References
- Heisenberg W. Über den anschaulichen inhalt der quantentheoretischen kinematik und mechanik. Z Physik. 1927;43(3–4):172–198.
- Maziarz RT, Yang H, Liu Q, et al. Real-world healthcare resource utilization and costs associated with tisagenlecleucel and axicabtagene ciloleucel among patients with diffuse large B-cell lymphoma: an analysis of hospital data in the United States. Leukemia Lymph. 2022;:1–11.
- Riedell PA, Walling C, Nastoupil LJ, et al. A multicenter retrospective analysis of outcomes and toxicities with commercial axicabtagene ciloleucel and tisagenlecleucel for relapsed/refractory aggressive B-cell lymphomas. Biol Blood Marrow Transplant. 2020;26(3):S41–S42.
- Zimmerman Savill KM, Klink AJ, Liassou D, et al. Real-World treatment of patients with large B-Cell lymphoma in the United States with chimeric antigen receptor T-Cell therapy. Blood. 2021;138(Supplement 1):4096–4096.
- Schuster SJ, Bishop MR, Tam CS, JULIET Investigators, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-Cell lymphoma. N Engl J Med. 2019;380(1):45–56.
- Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-Cell therapy in refractory large B-Cell lymphoma. N Engl J Med. 2017;377(26):2531–2544.
- Bishop MR, Dickinson M, Purtill D, et al. Second-Line tisagenlecleucel or standard care in aggressive B-Cell lymphoma. N Engl J Med. 2022;386(7):629–639.
- Locke FL, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel as second-line therapy for large B-Cell lymphoma. N Engl J Med. 2022;386(7):640–654.
- Bansal R, Paludo J, Holland A, et al. Outpatient practice pattern and remote patient monitoring for axicabtagene ciloleucel CAR-T therapy in patients with aggressive lymphoma. J Clin Oncol. 2021;39(15_suppl):7554–7554.
- Borogovac A, Keruakous AR, Bycko M, et al. Successful development of an outpatient chimeric antigen receptor (CAR) T cell therapy program. Blood. 2021;138(Supplement 1):4821–4821.
- Topp MS, van Meerten T, Houot R, et al. Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma. Br J Haematol. 2021;195(3):388–398.
- Oluwole OO, Bouabdallah K, Muñoz J, et al. Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma. Br J Haematol. 2021;194(4):690–700.
- Kamdar M, Solomon SR, Arnason JE, et al. Lisocabtagene maraleucel (liso-cel), a CD19-Directed chimeric antigen receptor (CAR) T cell therapy, versus standard of care (SOC) with salvage chemotherapy (CT) followed by autologous stem cell transplantation (ASCT) as Second-Line (2L) treatment in patients (pts) with relapsed or refractory (R/R) large B-Cell lymphoma (LBCL): results from the randomized phase 3 transform study. Blood. 2021;138(Supplement 1):91–91.
- National Comprehensive Cancer Network. 2022. B-Cell Lymphoma (version 4.2022). Retrieved from https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf